In clinical trials, treatment with tirzepatide produced superior weight loss and glycemic control compared to GLP-1RAs3,17, suggesting that agonism at both the GIPR and GLP-1R is beneficial in humans with type 2 diabetes. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.